Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$3.74
Price+0.40%
$0.01
$14.750m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$968k
-
1y CAGR-
3y CAGR-
5y CAGR-$59.853m
-
1y CAGR-
3y CAGR-
5y CAGR-$15.50
-
1y CAGR-
3y CAGR-
5y CAGR$31.986m
$35.545m
Assets$3.559m
Liabilities$1.017m
Debt2.9%
-
Debt to EBITDA-$70.700m
-
1y CAGR-
3y CAGR-
5y CAGR